STAT

With NASH results, Intercept Pharma will seek approval for first-ever treatment for fatty liver condition

With new clinical trial results, Intercept Pharma will seek approval for first-ever treatment for NASH, a fatty liver condition.

Intercept Pharmaceuticals (ICPT) said Tuesday that an experimental medicine to treat the fatty liver disease known as NASH achieved its primary goal in a Phase 3 clinical trial, giving it a shot at becoming the first drug to treat the condition and turning it into a potential blockbuster commercial opportunity.

Based on the data collected

You're reading a preview, sign up to read more.

More from STAT

STAT3 min readSociety
Mental Health Care Accounts For A Growing Number Of Private Insurance Claims, Report Finds
Mental health care is accounting for a growing number of private insurance claims, according to a new report.
STAT1 min readWellness
Listen: Drug Pricing Partisanship, Tech’s March Into Health Care, And Tinder For Clinical Trials
Has drug price reform already stalled? How far has tech come in medicine? All that and more on the new episode of our #biotech #podcast, "The Readout LOUD."
STAT4 min readPolitics
In Washington, A Partisan Approach To Lowering Drug Costs Leaves Democrats Doubting Their Own Party Leadership
Even some Democratic lawmakers are questioning Speaker Pelosi’s strategy to couple legislation to lower prescription drug costs with far more contentious Obamacare bills.